Shares of GoodRx Holdings Inc. (GDRX) surged 5.52% in pre-market trading on Thursday, following the prescription savings platform company's mixed fourth quarter 2024 results but upbeat outlook for 2025.
For the fourth quarter, GoodRx reported adjusted earnings per share of $0.09, matching analyst estimates. However, revenue of $198.6 million came in slightly below the $199.8 million expected by Wall Street. Despite the Q4 revenue miss, investors appeared encouraged by the company's guidance for continued growth momentum in 2025.
For the full year 2025, GoodRx forecast revenue in the range of $810 million to $840 million, representing year-over-year growth of 2% to 6%. The company also expects adjusted EBITDA of $270 million to $286 million, up 4% to 10% from 2024 levels. Management cited expanding relationships across the pharmacy ecosystem and plans to broaden the company's solution set as key drivers of the positive 2025 outlook.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.